Insulet Maps Out Next-Gen Diabetes Devices Through 2028

Insulet has announced plans to expand its Omnipod portfolio and develop a fully closed-loop insulin delivery system for people with Type 2 diabetes. The company expects to launch its next flagship patch pump, Omnipod 6, in 2027, followed by a fully automated Type 2 system in 2028. Unlike current systems, the Type 2 platform will not require meal entry or carb counting, making it easier to use and suitable for primary care. A pivotal trial is planned for 2026 after completing enrollment in the Evolution 2 feasibility study.

Omnipod 6 will remain a hybrid closed-loop device but incorporate a learning algorithm to better tailor insulin delivery. Insulet is also updating Omnipod 5 with a lower target range, expanded CGM compatibility—including Abbott’s Libre 3 Plus—and a new data platform. The automated insulin delivery market is projected to grow from $5.7 billion to $9 billion by 2028, with Insulet expecting $2.7 billion in 2025 sales.

02-12-2025